Alnylam Pharmaceuticals
ALNY
#788
Rank
S$39.86 B
Marketcap
S$297.92
Share price
3.63%
Change (1 day)
-50.10%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): S$7.13

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is S$7.08. In 2025 the company made an earnings per share (EPS) of S$2.64.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)S$7.13170.14%
2025S$2.64
2023S-$4.52-62%
2022S-$11.8929.03%
2021S-$9.22-3.36%
2020S-$9.54-8.48%
2019S-$10.427.67%
2018S-$9.6839.74%
2017S-$6.9312.94%
2016S-$6.1338.84%
2015S-$4.42-32.88%
2014S-$6.58259.44%
2013S-$1.83-31.25%
2012S-$2.66

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
S$8.53 20.43%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
S$2.44-65.59%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
S$53.66 657.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
S-$3.37-147.56%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
S-$0.93-113.20%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
S-$0.12-101.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
S$0.81-88.61%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
S-$4.26-160.22%๐Ÿ‡บ๐Ÿ‡ธ USA